Literature DB >> 29187559

Reprograming of Glucose Metabolism by Zerumbone Suppresses Hepatocarcinogenesis.

Nissar Ahmad Wani1,2, Bo Zhang3, Kun-Yu Teng2,4, Juan M Barajas2,4, Tasneem Motiwala5, Peng Hu2,4, Lianbo Yu5, Rafael Brüschweiler3,6,7, Kalpana Ghoshal8,4, Samson T Jacob9,2.   

Abstract

Hepatocellular carcinoma (HCC) is the most prevalent and highly aggressive liver malignancy with limited therapeutic options. Here, the therapeutic potential of zerumbone, a sesquiterpene derived from the ginger plant Zingiber zerumbet, against HCC was explored. Zerumbone inhibited proliferation and clonogenic survival of HCC cells in a dose-dependent manner by arresting cells at the G2-M phase and inducing apoptosis. To elucidate the underlying molecular mechanisms, a phosphokinase array was performed that showed significant inhibition of the PI3K/AKT/mTOR and STAT3 signaling pathways in zerumbone-treated HCC cells. Gene expression profiling using microarray and analysis of microarray data by Gene Set Enrichment Analysis (GSEA) and Ingenuity Pathway Analysis (IPA) revealed that zerumbone treatment resulted in significant deregulation of genes regulating apoptosis, cell cycle, and metabolism. Indeed, tracing glucose metabolic pathways by growing HCC cells with 13C6-glucose and measuring extracellular and intracellular metabolites by 2D nuclear magnetic resonance (NMR) spectroscopy showed a reduction in glucose consumption and reduced lactate production, suggesting glycolytic inhibition. In addition, zerumbone impeded shunting of glucose-6-phosphate through the pentose phosphate pathway, thereby forcing tumor cells to undergo cell-cycle arrest and apoptosis. Importantly, zerumbone treatment suppressed subcutaneous and orthotopic growth and lung metastasis of HCC xenografts in immunocompromised mice. In conclusion, these findings reveal a novel and potentially effective therapeutic strategy for HCC using a natural product that targets cancer cell metabolism.Implications: Dietary compounds, like zerumbone, that impact cell cycle, apoptosis, and metabolic processes may have therapeutic benefits for HCC patients. Mol Cancer Res; 16(2); 256-68. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29187559      PMCID: PMC5805640          DOI: 10.1158/1541-7786.MCR-17-0304

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  32 in total

1.  Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha.

Authors:  Bo Wang; Shu-Hao Hsu; Wendy Frankel; Kalpana Ghoshal; Samson T Jacob
Journal:  Hepatology       Date:  2012-06-05       Impact factor: 17.425

2.  mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells.

Authors:  Raju V Pusapati; Anneleen Daemen; Catherine Wilson; Wendy Sandoval; Min Gao; Benjamin Haley; Andreas R Baudy; Georgia Hatzivassiliou; Marie Evangelista; Jeff Settleman
Journal:  Cancer Cell       Date:  2016-03-24       Impact factor: 31.743

3.  Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells.

Authors:  Keiyo Takubo; Go Nagamatsu; Chiharu I Kobayashi; Ayako Nakamura-Ishizu; Hiroshi Kobayashi; Eiji Ikeda; Nobuhito Goda; Yasmeen Rahimi; Randall S Johnson; Tomoyoshi Soga; Atsushi Hirao; Makoto Suematsu; Toshio Suda
Journal:  Cell Stem Cell       Date:  2013-01-03       Impact factor: 24.633

Review 4.  Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer.

Authors:  Evan C Lien; Costas A Lyssiotis; Lewis C Cantley
Journal:  Recent Results Cancer Res       Date:  2016

5.  Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production.

Authors:  Ryan Reyes; Nissar A Wani; Kalpana Ghoshal; Samson T Jacob; Tasneem Motiwala
Journal:  Gene Expr       Date:  2016-11-16

Review 6.  Regulation of glucose metabolism in hepatocarcinogenesis by microRNAs.

Authors:  Ryan K Reyes; Tasneem Motiwala; Samson T Jacob
Journal:  Gene Expr       Date:  2014

Review 7.  Key cell signaling pathways modulated by zerumbone: role in the prevention and treatment of cancer.

Authors:  Remya Prasannan; Karunakaran A Kalesh; Muthu K Shanmugam; Alamelu Nachiyappan; Lalitha Ramachandran; An H Nguyen; Alan Prem Kumar; Manikandan Lakshmanan; Kwang Seok Ahn; Gautam Sethi
Journal:  Biochem Pharmacol       Date:  2012-07-27       Impact factor: 5.858

8.  NMR method for measuring carbon-13 isotopic enrichment of metabolites in complex solutions.

Authors:  Ian A Lewis; Ryan H Karsten; Mark E Norton; Marco Tonelli; William M Westler; John L Markley
Journal:  Anal Chem       Date:  2010-06-01       Impact factor: 6.986

9.  Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer.

Authors:  Qi Wang; Prashanth T Bhaskar; Krushna C Patra; Luke Miller; Zebin Wang; Will Wheaton; Navdeep Chandel; Markku Laakso; William J Muller; Eric L Allen; Abhishek K Jha; Gromoslaw A Smolen; Michelle F Clasquin; Brooks Robey; Nissim Hay
Journal:  Cancer Cell       Date:  2013-08-01       Impact factor: 31.743

10.  Genetic variants in glucose-6-phosphate isomerase gene as prognosis predictors in hepatocellular carcinoma.

Authors:  Zhuomin Lyu; Yibing Chen; Xu Guo; Feng Zhou; Zhaoyong Yan; Jinliang Xing; Jiaze An; Hongxin Zhang
Journal:  Clin Res Hepatol Gastroenterol       Date:  2016-06-07       Impact factor: 2.947

View more
  4 in total

Review 1.  Gingers and Their Purified Components as Cancer Chemopreventative Agents.

Authors:  John F Lechner; Gary D Stoner
Journal:  Molecules       Date:  2019-08-07       Impact factor: 4.411

Review 2.  OMICS Applications for Medicinal Plants in Gastrointestinal Cancers: Current Advancements and Future Perspectives.

Authors:  Rongchen Dai; Mengfan Liu; Xincheng Xiang; Yang Li; Zhichao Xi; Hongxi Xu
Journal:  Front Pharmacol       Date:  2022-02-04       Impact factor: 5.810

Review 3.  Medicinal Plants for the Treatment of Gastrointestinal Cancers From the Metabolomics Perspective.

Authors:  Wei Guo; Peng Cao; Xuanbin Wang; Min Hu; Yibin Feng
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

4.  Evaluation of Non-Uniform Sampling 2D 1H-13C HSQC Spectra for Semi-Quantitative Metabolomics.

Authors:  Bo Zhang; Robert Powers; Elizabeth M O'Day
Journal:  Metabolites       Date:  2020-05-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.